Highlights from the PER® CME activity "Medical Crossfire®: Precision Oncology in NSCLC – Translating HER2 and TROP2 Innovation into Practice-Changing Care" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.

In this podcast, focusing on precision oncology in non-small cell lung cancer (NSCLC), experts Helena Yu, MD; Jacob Sands, MD; and Sarah Goldberg MD, MPH; will discuss the rapidly evolving landscape of Human Epidermal growth factor Receptor 2 (HER2)- and Trophoblast cell-surface antigen 2 (TROP2)-directed therapies in NSCLC. The podcast covers the spectrum of targeted agents from antibody-drug conjugates (ADCs) to novel HER2-selective tyrosine kinase inhibitors (TKIs), along with key clinical trial data and practical strategies for managing the unique adverse event profiles associated with these treatments.

Earn CME credit by completing the full accredited activity (available through June 30, 2027): https://www.gotoper.com/courses/medical-crossfire-precision-oncology-in-nsclc-translating-her2-and-trop2-innovation-into-practice-changing-care-mr5q

This podcast, including the narration, was developed by PER® (Physicians’ Education Resource®, LLC) editorial staff from the full online CME activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool. The podcast contains no product advertising. The full activity is supported by educational grants from AstraZeneca Pharmaceuticals; Daiichi Sankyo, Inc.; and Gilead Sciences, Inc.

This content is for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Faculty may discuss investigational or off-label uses; consult prescribing information for any products discussed.

Highlights from the PER® CME activity "Cases and Conversations: Applying the Evidence – Real-World Strategies to Optimize Care for Patients With Myelofibrosis" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.

In this podcast, experts Ruben Mesa, MD, FACP; Andrew Kuykendall, MD; and Sangeetha Venugopal, MD, MS; discuss evolving management strategies for patients with MF, and considerations for selecting therapy based on patient-related and disease-related factors.

Earn CME credit by completing the full accredited activity (available through June 29, 2027): https://www.gotoper.com/courses/cases-and-conversations-applying-the-evidence-real-world-strategies-to-optimize-care-for-patients-with-myelofibrosis-jadn
This podcast, including the narration, was developed by PER® (Physicians’ Education Resource®, LLC) editorial staff from the full online CME activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool. The podcast contains no product advertising. The full activity is supported by educational grants from Bristol Myers Squibb and PharmaEssentia.

This content is for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Faculty may discuss investigational or off-label uses; consult prescribing information for any products discussed.

Highlights from the PER® CME activity "Show Me the Data™: Redefining Treatment Paradigms in Triple-Negative Breast Cancer Across the Disease Continuum" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.

In this podcast, experts Hope S. Rugo, MD, FASCO; Neil M. Iyengar, MD; Heather McArthur, MD, MPH; and Jason Aboudi Mouabbi, MD; discuss the latest data to inform management of patients with early-stage triple negative breast cancer (TNBC).

Earn CME credit by completing the full accredited activity (available through June 30, 2027): https://www.gotoper.com/courses/show-me-the-data-redefining-treatment-paradigms-in-triple-negative-breast-cancer-across-the-disease-continuum-h5kn
This podcast, including the narration, was developed by PER® (Physicians’ Education Resource®, LLC) editorial staff from the full online CME activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool. The podcast contains no product advertising. The full activity is supported by educational grants from AstraZeneca Pharmaceuticals; BioNTech; Daiichi Sankyo, Inc.; and Merck Sharp & Dohme LLC.

This content is for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Faculty may discuss investigational or off-label uses; consult prescribing information for any products discussed.

Highlights from the PER® CME activity "Medical Crossfire®: Closing Clinical Practice Gaps in Hepatobiliary Cancer With Emerging Immunotherapies and Delivery Innovations" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.

In this podcast, experts Ghassan Abou-Alfa, MD, JD, MBA, PhD (hc), Riad Salem, MD, MBA, Rachna T. Shroff, MD, MS, FASCO, and Arndt Vogel, MD, PhD discuss closing clinical practice gaps in hepatobiliary cancer with emerging immunotherapies and delivery innovations.

Earn CME credit by completing the full accredited activity (available through June 30, 2027): https://www.gotoper.com/courses/medical-crossfire-closing-clinical-practice-gaps-in-hepatobiliary-cancer-with-emerging-immunotherapies-and-delivery-innovations-h754
This podcast, including the narration, was developed by PER® (Physicians’ Education Resource®, LLC) editorial staff from the full online CME activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool. The podcast contains no product advertising. The full activity is supported by an educational grant from AstraZeneca Pharmaceuticals.

This content is for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Faculty may discuss investigational or off-label uses; consult prescribing information for any products discussed.

Welcome to OncLive On Air®! I’m your host today, Courtney Flaherty.

OncLive On Air is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.

In this episode of OncLive On Air, Gerald Soff, MD, sat down with OncLive to discuss findings from the phase 3 RECITE trial (NCT03362177), which evaluated romiplostim for the management of chemotherapy-induced thrombocytopenia (CIT) in patients with gastrointestinal cancers.

Soff is a professor of clinical medicine in the Division of Hematology and chief of the Classical Hematology Section at the University of Miami Miller School of Medicine in Florida.

During the interview, Soff reviewed the longstanding unmet need for effective CIT management and explained how thrombopoietin receptor agonists, such as romiplostim, may help maintain platelet counts and preserve chemotherapy delivery; highlighted key findings from RECITE; and discussed the concept of relative dose intensity and why maintaining full-dose chemotherapy remains an important goal in GI oncology care.

_____

That’s all we have for today! Thank you for listening to this episode of OncLive On Air. Check back throughout the week for exclusive interviews with leading experts in the oncology field.

For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.

OncLive is also on social media. On X and BlueSky, follow us at @OncLive. On Facebook, like us at OncLive, and follow our OncLive page on LinkedIn.

If you liked today’s episode of OncLive On Air, please consider subscribing to our podcast on Apple Podcasts, Spotify, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!

Thanks again for listening to OncLive On Air.

*OncLive On Air is available on: Apple Podcasts, Spotify, CastBox, Podcast Addict, Podchaser, RadioPublic, and TuneIn.

Highlights from the PER® CME activity "Cases and Conversations: Optimizing Oral SERD-Based Therapy After CDK4/6 Inhibition in HR+/HER2– MBC" — this podcast is not certified for credit. To participate in the full accredited activity and earn CME credit, use the link below.

In this podcast, experts Virginia Kaklamani, MD, DSc; Antonio Giordano, MD, PhD; Nadia Harbeck, MD, PhD; and Sarah Sammons, MD, discuss the use of oral SERD-based therapy in the treatment of HR+/HER2– metastatic breast cancer through a series of clinical cases.

Earn CME credit by completing the full accredited activity (available through June 30, 2027): https://www.gotoper.com/courses/cases-and-conversations-optimizing-oral-serd-based-therapy-after-cdk46-inhibition-in-hrher2-mbc-xv6m
This podcast, including the narration, was developed by PER® (Physicians’ Education Resource®, LLC) editorial staff from the full online CME activity developed with these faculty. The narration was voiced by a PER staff member or by an AI tool. The podcast contains no product advertising. The full activity is supported by an educational grant from Stemline Therapeutics, Inc.

This content is for educational purposes only and is not a substitute for the independent clinical judgment of a health care professional. Faculty may discuss investigational or off-label uses; consult prescribing information for any products discussed.